Literature DB >> 31593640

Exogenous miR-26a suppresses muscle wasting and renal fibrosis in obstructive kidney disease.

Aiqing Zhang1,2, Haidong Wang2,3, Bin Wang2,4, Yanggang Yuan5, Janet D Klein2, Xiaonan H Wang2.   

Abstract

Kidney fibrosis occurs in almost every type of chronic kidney disease. We found that microRNA (miR)-26a was decreased in the kidney, muscle, and exosomes of unilateral ureteral obstruction (UUO) mice. We hypothesized that exogenous miR-26 could suppresses renal fibrosis and muscle wasting in obstructive kidney disease. For this purpose, we generated exosomes that encapsulated miR-26, then injected these into skeletal muscle of UUO mice. The expression of miR-26a was elevated in serum exosomes from UUO mice following exosome-miR-26a injection. In these mice, muscle wasting has been ameliorated as evidenced by increased muscle weights. In addition, a muscle atrophy marker, myostatin, is increased in UUO muscle; provision of miR-26a abolished this increase. We detected a remote effect of exosomes containing miR-26a in UUO-induced renal fibrosis. The intervention of miR-26a attenuated UUO-induced renal fibrosis as determined by immunohistological assessment of α-smooth muscle actin and Masson's trichrome staining. Furthermore, exogenous miR-26a decreased the protein levels of 2 profibrosis proteins, connective tissue growth factor (CTGF) and TGF-β1, in UUO kidney. Our data showed that exosomes containing miR-26a prevented muscle atrophy by inhibiting the transcription factor forkhead box O1. Likewise, the exosome-carried miR-26a limited renal fibrosis by directly suppressing CTGF. Our findings provide an experimental basis for exosome-mediated therapy of muscle atrophy and renal fibrosis.-Zhang, A., Wang, H., Wang, B., Yuan, Y., Klein, J. D., Wang, X. H. Exogenous miR-26a suppresses muscle wasting and renal fibrosis in obstructive kidney disease.

Entities:  

Keywords:  CTGF; TGF-β1; UUO; exosome; muscle atrophy

Mesh:

Substances:

Year:  2019        PMID: 31593640      PMCID: PMC6894078          DOI: 10.1096/fj.201900884R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.834


  47 in total

Review 1.  Microvesicles and exosomes: new players in metabolic and cardiovascular disease.

Authors:  Charlotte Lawson; Jose M Vicencio; Derek M Yellon; Sean M Davidson
Journal:  J Endocrinol       Date:  2016-01-07       Impact factor: 4.286

2.  Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease.

Authors:  Liping Zhang; Vik Rajan; Eugene Lin; Zhaoyong Hu; H Q Han; Xiaolan Zhou; Yanping Song; Hosung Min; Xiaonan Wang; Jie Du; William E Mitch
Journal:  FASEB J       Date:  2011-01-31       Impact factor: 5.191

3.  Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass.

Authors:  Liping Zhang; Jenny Pan; Yanjun Dong; David J Tweardy; Yanlan Dong; Giacomo Garibotto; William E Mitch
Journal:  Cell Metab       Date:  2013-09-03       Impact factor: 27.287

4.  Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity.

Authors:  Xiaonan H Wang; Liping Zhang; William E Mitch; Joseph M LeDoux; Junping Hu; Jie Du
Journal:  J Biol Chem       Date:  2010-04-27       Impact factor: 5.157

5.  MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids.

Authors:  Xianghui Fu; Bingning Dong; Yan Tian; Philippe Lefebvre; Zhipeng Meng; Xichun Wang; François Pattou; Weidong Han; Xiaoqiong Wang; Fang Lou; Richard Jove; Bart Staels; David D Moore; Wendong Huang
Journal:  J Clin Invest       Date:  2015-05-11       Impact factor: 14.808

6.  Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.

Authors:  Marco Sandri; Claudia Sandri; Alex Gilbert; Carsten Skurk; Elisa Calabria; Anne Picard; Kenneth Walsh; Stefano Schiaffino; Stewart H Lecker; Alfred L Goldberg
Journal:  Cell       Date:  2004-04-30       Impact factor: 41.582

7.  Transfer of microRNA-486-5p from human endothelial colony forming cell-derived exosomes reduces ischemic kidney injury.

Authors:  Jose L Viñas; Dylan Burger; Joseph Zimpelmann; Randa Haneef; William Knoll; Pearl Campbell; Alex Gutsol; Anthony Carter; David S Allan; Kevin D Burns
Journal:  Kidney Int       Date:  2016-09-17       Impact factor: 10.612

8.  Exercise ameliorates chronic kidney disease-induced defects in muscle protein metabolism and progenitor cell function.

Authors:  Xiaonan H Wang; Jie Du; Janet D Klein; James L Bailey; William E Mitch
Journal:  Kidney Int       Date:  2009-07-29       Impact factor: 10.612

9.  The antifibrotic effects and mechanisms of microRNA-26a action in idiopathic pulmonary fibrosis.

Authors:  Haihai Liang; Chaoqian Xu; Zhenwei Pan; Ying Zhang; Zhidan Xu; Yingzhun Chen; Tianyu Li; Xuelian Li; Ying Liu; Longtao Huangfu; Ying Lu; Zhihua Zhang; Baofeng Yang; Samuel Gitau; Yanjie Lu; Hongli Shan; Zhimin Du
Journal:  Mol Ther       Date:  2014-03-05       Impact factor: 11.454

10.  Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation.

Authors:  Q M Wang; C J Fiol; A A DePaoli-Roach; P J Roach
Journal:  J Biol Chem       Date:  1994-05-20       Impact factor: 5.157

View more
  16 in total

1.  Serum extracellular vesicle miR-203a-3p content is associated with skeletal muscle mass and protein turnover during disuse atrophy and regrowth.

Authors:  Douglas W Van Pelt; Ivan J Vechetti; Marcus M Lawrence; Kathryn L Van Pelt; Parth Patel; Benjamin F Miller; Timothy A Butterfield; Esther E Dupont-Versteegden
Journal:  Am J Physiol Cell Physiol       Date:  2020-07-08       Impact factor: 4.249

2.  In vivo two-photon microscopy reveals the contribution of Sox9+ cell to kidney regeneration in a mouse model with extracellular vesicle treatment.

Authors:  Kaiyue Zhang; Shang Chen; Huimin Sun; Lina Wang; Huifang Li; Jinglei Zhao; Chuyue Zhang; Nana Li; Zhikun Guo; Zhibo Han; Zhong-Chao Han; Guoguang Zheng; Xiangmei Chen; Zongjin Li
Journal:  J Biol Chem       Date:  2020-07-08       Impact factor: 5.157

3.  Adipose mesenchymal stem cell-derived extracellular vesicles containing microRNA-26a-5p target TLR4 and protect against diabetic nephropathy.

Authors:  Yurui Duan; Qingyang Luo; Yun Wang; Yali Ma; Fang Chen; Xiaoguang Zhu; Jun Shi
Journal:  J Biol Chem       Date:  2020-06-24       Impact factor: 5.157

Review 4.  Pathophysiological mechanisms leading to muscle loss in chronic kidney disease.

Authors:  Xiaonan H Wang; William E Mitch; S Russ Price
Journal:  Nat Rev Nephrol       Date:  2021-11-08       Impact factor: 42.439

Review 5.  Stem cell-based treatment of kidney diseases.

Authors:  Binbin Pan; Guoping Fan
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-11

6.  MiR-26a inhibits the inflammatory response of microglia by targeting HMGA2 in intracerebral hemorrhage.

Authors:  Jun Jin; Feng Zhou; Jie Zhu; Weixian Zeng; Yong Liu
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

Review 7.  MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application.

Authors:  Linsey J F Peters; Jürgen Floege; Erik A L Biessen; Joachim Jankowski; Emiel P C van der Vorst
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

8.  Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia.

Authors:  Chunxiao Miao; Wanli Zhang; Lixing Feng; Xiaofan Gu; Qiang Shen; Shanshan Lu; Meng Fan; Yiwei Li; Xianling Guo; Yushui Ma; Xuan Liu; Hui Wang; Xiongwen Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2021-04-24       Impact factor: 8.886

Review 9.  Extracellular Vesicles in Organ Fibrosis: Mechanisms, Therapies, and Diagnostics.

Authors:  David R Brigstock
Journal:  Cells       Date:  2021-06-25       Impact factor: 6.600

Review 10.  Exosomes in Nephropathies: A Rich Source of Novel Biomarkers.

Authors:  Christos Masaoutis; Samer Al Besher; Ioannis Koutroulis; Stamatios Theocharis
Journal:  Dis Markers       Date:  2020-08-12       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.